Tvardi Therapeutics, Inc.
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers. Its pipeline centers on TTI-101 and TTI-109, with development programs spanning preclinical and early clinical stages.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule drug candidates in clinical and early development.
Discovery-stage programs for additional fibrosis and oncology indications.
Internal and outsourced work to advance target biology, chemistry, and trials.
Products
Reported · share of revenue- Other Revenue60.6 %
- Collaborative Revenue29.2 %
- Commercial Supply Revenue9.0 %
- Clinical Compound Revenue1.2 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Tvardi does not currently sell approved products, so it has no commercial customer base today. If its candidates are approved, the end users would be physicians treating patients with fibrosis-related diseases or cancers, while reimbursement would depend on payors such as Medicare, Medicaid, and commercial insurers. The company may also generate future value through collaboration or license partners rather than direct product sales.
Would prescribe Tvardi's therapies if approved for fibrosis or oncology indications.
Medicare, Medicaid, and managed care organizations that influence access and uptake.
Potential end users for TTI-101 and TTI-109 in diseases such as IPF.
Potential end users for TTI-101 in HCC and other solid tumors.
Pharma or biotech collaborators that may license or co-develop programs.
Strategy
Tvardi’s strategy is to advance TTI-101 and TTI-109 through clinical and preclinical development toward regulatory approval and eventual commercialization. It also seeks to preserve optionality through partnerships, licensing, and external financing to support long development timelines and capital needs.
Clinical progress is the main value driver for a company without approved products.
Development-stage biopharma requires ongoing capital before any product revenue.
Multiple shots on goal can improve the chance of creating a viable commercial asset.
Geography
Tvardi is headquartered in the United States and operates as a U.S.-based biopharmaceutical developer. Its business is global in competitive scope because its target indications attract large multinational drug developers, but the company’s reported operations and financing are centered in the U.S. As a development-stage company, geography matters mainly through U.S. clinical, regulatory, and reimbursement pathways.
Risks
Tvardi faces the typical risks of a clinical-stage biopharmaceutical company: uncertain trial outcomes, regulatory approval risk, and the possibility that approved products may not gain market acceptance or reimbursement. It also has a limited operating history, no product revenue, and a stated going-concern risk, making future financing and execution central to the business.
- Clinical development failureImpact: CriticalLikelihood: High
TTI-101 and TTI-109 are still in early development and may not show adequate efficacy or safety.
Exposure: Lead programs
- Financing and going-concern riskImpact: CriticalLikelihood: High
The company expects to need substantial additional funding and may not obtain it on acceptable terms.
Exposure: Corporate liquidity
- Competition from larger drug developersImpact: HighLikelihood: Medium
Major biopharma companies have greater resources and may reach the market first.
Exposure: Fibrosis and HCC indications
- Commercial adoption and reimbursement riskImpact: HighLikelihood: Low
Even approved therapies may face limited physician uptake or payor coverage.
Exposure: Future product sales
- Limited operating historyImpact: MediumLikelihood: High
The company has a short track record, making execution and forecasting difficult.
Exposure: Corporate execution
Accounting
Judgemental itemsClinical and preclinical vendor invoices may be recognized before or after cash payment, affecting period expense timing.
Impact: R&D expense and liabilities
Employee and director equity awards can be a significant non-cash expense for a small biotech.
Impact: Operating expenses and equity
Marketable securities must be measured and classified appropriately, affecting other income and balance sheet presentation.
Impact: Cash equivalents, investments, and earnings
Net assets acquired in the merger and any future intangible assets may require valuation and impairment testing.
Impact: Assets, goodwill/intangibles, and future charges
Similar listed companies
Publicly listed companies with a comparable business focus.
Trevi Therapeutics, Inc.
TRVI · Pharmaceutical Preparations
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
TG Therapeutics, Inc
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
TScan Therapeutics, Inc.
TCRX · Biological Products, (No Diagnostic Substances)
TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer.
Aardvark Therapeutics, Inc.
AARD · Pharmaceutical Preparations
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Last updated: 24/09/2026